Cannabis: A Treasure Trove or Pandora's Box?

Solymosi, Katalin; Köfalvi, Attila

doi:10.2174/1389557516666161004162133

Cited by 77 publications

(132 citation statements)

References 897 publications

(1,547 reference statements)

Supporting

Mentioning

127

Contrasting

Unclassified

Order By: Relevance

“…The exact pharmacological identification of the receptor influenced by the cannabinoid compound used in this work is outside its objective. However, there is evidence that supports the possibility of the presently described actions of WIN 55,212‐2 being mediated through CB 1 R. WIN 55‐212,2 is one of the most commonly used cannabinomimetics to study the role of the CB 1 R and the CB 2 R (Solymosi and Köfalvi ), showing similar preference for activating both receptors (Pertwee et al . ).…”

Section: Discussionmentioning

confidence: 97%

“…; Pertwee et al . ; Solymosi and Köfalvi ). We previously showed that the CB 1 R selective antagonist (AM 251) abolished the impact of acute WIN 55,212‐2 administration on recognition memory, which was evaluated with the same NORT paradigm and using mice of the same age as used in this study (Mouro et al .…”

Section: Discussionmentioning

confidence: 99%

“…This protocol was designed to minimize the tolerance to WIN 55,212‐2 that may develop during chronic continuous administration (see Maldonado ; Hampson et al . ; Solymosi and Köfalvi ). For further detail on the treatment and experimental protocol see Fig.…”

Section: Methodsmentioning

confidence: 99%

See 2 more Smart Citations

Chronic, intermittent treatment with a cannabinoid receptor agonist impairs recognition memory and brain network functional connectivity

Mouro

Ribeiro

Sebastião

et al. 2018

Journal of Neurochemistry

View full text Add to dashboard Cite

Elucidating how cannabinoids affect brain function is instrumental for the development of therapeutic tools aiming to mitigate ‘on target’ side effects of cannabinoid‐based therapies. A single treatment with the cannabinoid receptor agonist, WIN 55,212‐2, disrupts recognition memory in mice. Here, we evaluate how prolonged, intermittent (30 days) exposure to WIN 55,212‐2 (1 mg/kg) alters recognition memory and impacts on brain metabolism and functional connectivity. We show that chronic, intermittent treatment with WIN 55,212‐2 disrupts recognition memory (Novel Object Recognition Test) without affecting locomotion and anxiety‐like behaviour (Open Field and Elevated Plus Maze). Through 14C‐2‐deoxyglucose functional brain imaging we show that chronic, intermittent WIN 55,212‐2 exposure induces hypometabolism in the hippocampal dorsal subiculum and in the mediodorsal nucleus of the thalamus, two brain regions directly involved in recognition memory. In addition, WIN 55,212‐2 exposure induces hypometabolism in the habenula with a contrasting hypermetabolism in the globus pallidus. Through the application of the Partial Least Squares Regression (PLSR) algorithm to the brain imaging data, we observed that prolonged WIN 55,212‐2 administration alters functional connectivity in brain networks that underlie recognition memory, including that between the hippocampus and prefrontal cortex, the thalamus and prefrontal cortex, and between the hippocampus and the perirhinal cortex. In addition, our results support disturbed lateral habenula and serotonin system functional connectivity following WIN 55,212‐2 exposure. Overall, this study provides new insight into the functional mechanisms underlying the impact of chronic cannabinoid exposure on memory and highlights the serotonin system as a particularly vulnerable target.

show abstract

Section: Discussionmentioning

confidence: 97%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Chronic, intermittent treatment with a cannabinoid receptor agonist impairs recognition memory and brain network functional connectivity

Mouro

Ribeiro

Sebastião

et al. 2018

Journal of Neurochemistry

View full text Add to dashboard Cite

show abstract

“…More than a 100 pCB have been identified, of which the psychotropic (–)- trans -Δ 9 -tetrahydrocannabidiol (THC) and the nonpsychotropic (–)-cannabidiol (CBD) are the best studied [14-16]. THC and CBD mediate a broad spectrum of biological actions including analgesic, antiemetic, and anti-inflammatory effects [12-14].…”

Section: Cannabinoids and The Endocannabinoid Systemmentioning

confidence: 99%

“…THC and CBD mediate a broad spectrum of biological actions including analgesic, antiemetic, and anti-inflammatory effects [12-14]. …”

Section: Cannabinoids and The Endocannabinoid Systemmentioning

confidence: 99%

Cannabinoids in Gynecological Diseases

Luschnig

Schicho

2019

Med Cannabis Cannabinoids

View full text Add to dashboard Cite

The endocannabinoid system (ECS) is a multifunctional homeostatic system involved in many physiological and pathological conditions. The ligands of the ECS are the endocannabinoids, whose actions are mimicked by exogenous cannabinoids, such as phytocannabinoids and synthetic cannabinoids. Responses to the ligands of the ECS are mediated by numerous receptors like the classical cannabinoid receptors (CB1 and CB2) as well as ECS-related receptors, e.g., G protein-coupled receptors 18 and 55 (GPR18 and GPR55), transient receptor potential ion channels, and nuclear peroxisome proliferator-activated receptors. The ECS regulates almost all levels of female reproduction, starting with oocyte production through to parturition. Dysregulation of the ECS is associated with the development of gynecological disorders from fertility disorders to cancer. Cannabinoids that act at the ECS as specific agonists or antagonists may potentially influence dysregulation and, therefore, represent new therapeutic options for the therapy of gynecological disorders.

show abstract

Neuronal and synaptic morphological alterations in the hippocampus of cannabinoid receptor type 1 knockout mice

Soriano

Vacotto

Brusco

et al. 2020

J of Neuroscience Research

View full text Add to dashboard Cite

The endocannabinoid system, which has been conserved evolutionarily from plants to vertebrates (Elphick & Egertová, 2005; Solymosi & Köfalvi, 2017), modulates synaptic transmission and consists of cannabinoid receptors type 1 (CB1R) and type 2 (CB2R), its endogenous ligands (anandamide and 2-arachidonoylglycerol) and enzymes involved in its metabolism (Lambert & Fowler, 2005). CB1R is widely expressed in the central nervous system in vertebrates, both in neurons and glial cells (Facchinetti, Del Giudice,

show abstract

Cannabis: A Treasure Trove or Pandora's Box?

Cited by 77 publications

References 897 publications

Chronic, intermittent treatment with a cannabinoid receptor agonist impairs recognition memory and brain network functional connectivity

Chronic, intermittent treatment with a cannabinoid receptor agonist impairs recognition memory and brain network functional connectivity

Cannabinoids in Gynecological Diseases

Neuronal and synaptic morphological alterations in the hippocampus of cannabinoid receptor type 1 knockout mice

Contact Info

Product

Resources

About